# Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement

> **NCT01094886** · PHASE3 · COMPLETED · sponsor: **Ortho-McNeil Janssen Scientific Affairs, LLC** · enrollment: 56 (actual)

## Conditions studied

- Arthritis
- Osteoarthritis, Knee
- Osteoarthritis, Hip
- Thromboembolism

## Interventions

- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT01094886
- **Lead sponsor:** Ortho-McNeil Janssen Scientific Affairs, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2017-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01094886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01094886, "Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01094886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*